Experts Tell Congressional Briefing FDA Lets Bad Generics On Market
This article was originally published in PharmAsia News
A group of physician experts and others told a U.S. Congressional briefing that many unqualified generic drugs are reaching the market despite FDA, many of them ineffective or harmful to patients.
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.